LWLijun Wang

Lijun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lijun Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Tinghong Kuang, Lijun Wang, Yaning Shi, Ji Cheng, Shifeng Pan

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide, involving multiple pathological mechanisms such as lipid metabolism disorders, oxidative stress, chronic inflammation, insulin resistance, and dysregulation of the gut–liver axis. Currently, there remains a lack of effective and long-term safe therapeutic strategies for MASLD, necessitating the development of novel interventions. Plant-derived exosome-like nanovesicles (PELNs) represent naturally secreted nanoscale vesicles derived from plant cells. Their advantages, including extensive availability, high biocompatibility, low immune activation, remarkable stability, and convenient oral administration, make them attractive platforms for therapeutic delivery. PELNs can not only encapsulate natural bioactive compounds such as polyphenols, alkaloids, terpenoids, and polysaccharides but also serve as drug delivery vehicles to achieve liver-targeted transport and synergistic therapy. Current evidence for PELNs in MASLD is predominantly preclinical. In vitro studies have provided mechanistic insights into their effects on lipid metabolism, oxidative stress, inflammatory signaling, and hepatocellular injury, whereas animal studies have demonstrated improvements in hepatic steatosis and related metabolic abnormalities for selected PELNs. A smaller number of studies have investigated tissue distribution, oral uptake, or preliminary biosafety. However, systematic pharmacokinetic, long-term toxicological, and target-species clinical evidence remains insufficient. Accordingly, the therapeutic effects discussed in this review should be interpreted primarily as preclinical findings, and the applicability of PELNs in veterinary practice remains to be established.

  • Modulating Host Lipid Metabolism via Gut Microbiota: Therapeutic Potential of Plant‐Derived Compounds

    by Lijun Wang, Ji Cheng, Weilong Peng, Yiqian Chen, Shifeng Pan, Yao Lu

    Lipid metabolic imbalance is a major contributor to metabolic disorders in humans and livestock, creating an urgent need for safe and effective regulatory approaches. Plant‐derived compounds, characterized by favorable bioavailability and low toxicity, serve as promising candidates that regulate host lipid metabolism through dynamic crosstalk with the gut microbiota. This review systematically investigates the bidirectional crosstalk between plant bioactive compounds (e.g., polysaccharides, flavonoids, saponins and polyphenols) and the gut microbiota. We detail how gut microbes metabolize these compounds to enhance their bioactivity and bioavailability, while plant extracts reshape microbial community structure to enrich beneficial taxa. Furthermore, we elucidate the mechanisms underlying lipid metabolism regulation, focusing on three critical signaling pathways: (1) SCFAs‐GPR43/41 signaling, (2) TLR4/NF‐κB inflammation suppression, and (3) bile acid‐FXR axis modulation. Collectively, this review synthesizes emerging evidence on plant‐microbiota interactions as a novel therapeutic strategy to restore lipid homeostasis in animal models, offering foundational insights for agricultural and biomedical applications.

  • Open Access

    Recent Advances in Natural Products for Colitis: Mechanisms and Translational Perspectives

    by Fulin Jin, Yaning Shi, Lijun Wang, Tinghong Kuang, Keyan Ren, Jiaye Xu, Yifan Zhang, Changchang Niu, Ji Cheng, Shifeng Pan

    Colitis is a chronic relapsing inflammatory disorder characterized by persistent mucosal inflammation, epithelial barrier disruption, oxidative stress, immune dysregulation, and gut microbiota imbalance. Although current therapies have improved disease management, their long-term use is still limited by incomplete response, relapse, adverse effects, and high cost. Natural products have attracted increasing attention as promising candidates for colitis intervention because of their structural diversity, broad bioactivity, and multitarget regulatory potential. In veterinary medicine, colitis and colitis-related intestinal inflammatory disorders are also clinically relevant in companion animals, horses, and food-producing animals, where they contribute to diarrhea, impaired intestinal barrier function, reduced performance, treatment costs, and antimicrobial-use concerns. Therefore, natural products may have additional value as adjunctive, nutritional, or microbiota-modulating strategies in veterinary and comparative gastroenterology. This review summarizes the major categories of natural products investigated for colitis, including flavonoids, polyphenols, alkaloids, terpenoids, saponins, polysaccharides, plant extracts, and traditional herbal formulas, and discusses their principal mechanisms of action, such as anti-inflammatory activity, attenuation of oxidative stress, restoration of intestinal barrier integrity, modulation of immune responses, regulation of gut microbiota, and control of programmed cell death. We also highlight the major limitations of current research, including overreliance on preclinical models, insufficient target validation, poor bioavailability, and limited clinical evidence. Overall, natural products represent an important source of therapeutic candidates for colitis, but their clinical translation will require deeper mechanistic studies, standardized evaluation, and well-designed clinical investigations. Importantly, future studies should distinguish phenotype-associated changes from causal mechanisms by integrating direct target engagement, functional rescue experiments, microbiota-causality validation, and standardized pharmacokinetic and safety assessment.

  • Open Access

    Oral supplementation of sodium butyrate prevents lipid metabolism disorders and intestinal injury by modulating immunity, intestinal barrier functions, and gut microbiota in a corticosterone-induced chronic stress model in mice

    by Fei Li, Lijun Wang, Ji Cheng, Shifeng Pan, Yao Lu

    In intensive livestock and poultry farming, chronic stress poses a significant threat to animal health, primarily through its impact on butyric acid levels and intestinal microbiota balance. In our previous study, we found that the intestinal butyric acid level was significantly reduced in chronic stress models, suggesting that butyrate supplementation should be an effective anti-chronic stress strategy. Therefore, in this study, we aimed to investigate whether sodium butyrate (NaBu) prevents chronic stress-induced lipid metabolism disorders and intestinal injury by reducing intestinal damage and remodeling the microbiota. In vitro models, IEC-6 cells, a small intestinal epithelial cell line, were divided into three groups, including control (CON), corticosterone (CORT, 400 μM) and CORT + NaBu (400 μM CORT + 1 mM NaBu). In vivo models, sixty mice were divided into CON, CORT (intraperitoneal injection of 20 mg/kg CORT) and CORT + NaBu (intraperitoneal injection of 20 mg/kg CORT + intragastric gavage with 200 mg/kg NaBu). The results showed that NaBu effectively reversed CORT-induced IEC-6 migration inhibition, inhibited apoptosis, and restored barrier function, which was associated with downregulated IL-12 and upregulated LRP5 expression. In addition, NaBu administration prevented anorexia, promoted body weight gain, and improved lipid metabolism in a corticosterone-induced chronic stress model in mice, as evidenced by a significant reduction of serum alkaline phosphatase (AKP) and Low-density lipoprotein cholesterol (LDL-C). Histopathological staining and scanning electron microscopy analyses revealed that NaBu treatment restored the normal villi morphology of the small intestinal villi and mitigated epithelial cell damage caused by CORT. 16S rRNA sequencing demonstrated that NaBu facilitated intestinal microbiota remodeling, marked by significant increases in Desulfobacterota and Bacillus abundance and decreases in Proteobacteria and Enterorhabdus abundances. Furthermore, analysis suggests that CORT-induced chronic stress may disrupt the cecal microbiota-metabolite axis and lead to intestinal injury and metabolic abnormalitiesbased on previous metabolic evidence and current results of microbial imbalance and downstream metabolic/intestinal abnormalities. These findings indicate that NaBu exerts a protective role in the prevention of chronic stress-related disorders, providing a potential prophylactic strategy for animals at high risk of stress exposure.


  • Ssc‐miR‐130b Inhibits Lipid Accumulation in Porcine Intramuscular Preadipocytes by Activating Apoptosis via Bcl‐2/Bax/Caspase‐3 Signaling Pathway

    by Lulu Li, Yongfang Chen, Lijun Wang, Ji Cheng, Yao Lu, Shifeng Pan

    MicroRNAs (miRNAs) play pivotal roles in intramuscular fat (IMF) deposition and determine animal meat quality. The study aimed to investigate the effect of miR‐130b on adipogenesis in porcine intramuscular preadipocytes (PIMPA). In the study, PIMPA were isolated from longissimus dorsi muscle and cultured until 85%–90% confluence. The cells then subjected to adipogenic induction and transient transfections with miR‐130b mimic, miR‐130b inhibitor, and their corresponding controls (mNC and iNC). Oil red O staining was performed to detect lipid accumulation. Differentially expressed (DE) mRNAs were screened by transcriptome sequencing, and enriched functional pathways were identified through GO and KEGG analysis. The results demonstrated that numerous DE mRNAs were identified between the miR‐130b mimic and mNC groups, which were mainly enriched in apoptosis, autophagy, and AMPK signaling pathways. Mechanistically, miR‐130b overexpression significantly increased Bax expression, while reducing caspase‐3 and Bcl‐2 expression as well as Bcl‐2/Bax ratio. It also, and tended to increase cleaved caspase‐3/caspase‐3 ratio, thereby activating apoptosis and suppressing lipid accumulation. Furthermore, these above results can be significantly reversed by miR‐130b inhibition. In conclusion, our findings highlight that miR‐130b inhibits lipid accumulation by activating apoptosis via Bcl‐2/Bax/caspase‐3 signaling pathway in PIMPA, providing a reliable molecular target for improving animal meat quality and ameliorating human obesity.


  • Open Access

    Role of Gut Microbiota and Metabolite Remodeling on the Development and Management of Rheumatoid Arthritis: A Narrative Review

    by Yichen Yu, Fulin Jin, Lijun Wang, Ji Cheng, Shifeng Pan

    Rheumatoid arthritis (RA) is a chronic autoimmune disease that has a serious impact on both human health and animal production. The gut microbiota is a large and complex symbiotic ecosystem in animals, and the imbalance of gut microbiota is closely related to the pathogenesis of numerous diseases, including RA. The interactions among the gut microbiota, intestinal barrier, and immune system play key roles in maintaining intestinal homeostasis and affecting the development of RA. Regulating intestinal flora and metabolites provides new ideas for the prevention and treatment of RA. Probiotics can regulate the balance of intestinal flora and metabolites, improve the immune environment, and provide novel therapeutic strategies against RA. In order to summarize the role of gut microbiota and metabolite remodeling in the development and management of RA, this review will elaborate on the role of intestinal flora imbalance in the pathogenesis of RA and assess prospective therapeutic approaches that target the gut flora. Understanding the interaction among intestinal flora, metabolites, and RA will help to clarify the pathogenesis of RA and develop innovative and personalized therapeutic interventions against chronic autoimmune diseases.


  • Open Access

    Ssc-miR-130b Enhances Cell Proliferation and Represses Adipogenesis of Primary Cultured Intramuscular Preadipocytes in Pigs

    by Yunqiu Yang, Yongfang Chen, Lijun Wang, Min Du, Rui Zhang, Yao Lu, Shifeng Pan

    In the efforts towards germplasm innovation of livestock and poultry, strategies to improve meat quality have faced some increasingly challenging and dynamic concerns. Intramuscular fat (IMF) content and backfat thickness are two important traits contributing to meat quality. MicroRNAs (miRNAs)—a class of endogenous noncoding RNAs maintaining cell homeostasis by inhibiting target gene expression—have been proven as critical regulators of body fat deposition, thus affecting farm animal production. Our previous in vitro and in vivo models of pigs have clarified that miR-130b overexpression can obviously suppress adipogenesis of subcutaneous preadipocytes and lower backfat thickness. However, the way miR-130b regulates proliferation and adipogenesis of primary cultured porcine intramuscular preadipocytes (PIMPA) and the underlying mechanism are still unknown. PIMPA derived from longissimus dorsi muscle were employed to examine the role of miR-130b in proliferation and adipogenesis and to further elucidate its underlying mechanism. Lipid deposition in cytoplasm was evaluated by TG quantification and ORO-staining, and EDU-staining was employed to measure cell proliferation. Adipogenic and proliferation-related gene expression were conducted by qPCR and Western blot. MiR-130b overexpression markedly stimulated proliferation of PIMPA by increasing cell cycle-related gene expression. Furthermore, overexpression of miR-130b significantly inhibited adipogenic differentiation of PIMPA, mainly by inhibiting expression of adipogenic differentiation marker genes PPAR-γ and SREBP1. In addition, we proved that miR-130b significantly inhibited expression of PPAR-γ downstream target genes and ultimately repressed adipogenesis. Ssc-miR-130b accelerated proliferation but inhibited adipogenic differentiation of PIMPA, contributing to an enhanced knowledge of the function of ssc-miR-130b in lipid deposition, and providing potential implications for enhancing pork quality.


  • Open Access

    Rno-miR-130b Attenuates Lipid Accumulation Through Promoting Apoptosis and Inhibiting Differentiation in Rat Intramuscular Adipocytes

    by Yichen Yu, Yongfang Chen, Lijun Wang, Ji Cheng, Min Du, Shifeng Pan

    Our previous studies have shown that miR-130b can significantly inhibit subcutaneous fat deposition in pigs. This study aims to further investigate its effect on lipid accumulation at early-stage (24 and 48 h) and late-stage (7 d) adipogenic differentiation and to clarify potential mechanisms using primary rat intramuscular preadipocytes (IMAs). Results showed that at 24 h and 48 h, miR-130b overexpression significantly reduced lipid deposition by inhibiting proliferation and inducing apoptosis. Furthermore, miR-130b overexpression significantly inhibited the expression of cell cycle and apoptosis marker genes. Specifically, the mRNA expression of Ccnd1 tended to decrease, while the BCL2 protein level was significantly decreased at 48 h. In contrast, miR-130b inhibition significantly increased the BCL2 protein level. At 7 d, the miR-130b mimic significantly decreased intracellular TG content and tended to decrease Hsd11b1 mRNA expression while significantly promoting Lpl mRNA expression. Additionally, the miR-130b mimic significantly increased the CASP3 protein level and tended to decrease the BCL2 protein level. In conclusion, our data indicated for the first time that miR-130b could reduce lipid deposition in rat IMAs through different mechanisms: at the early stage of differentiation by inhibiting proliferation and promoting apoptosis and at the late stage by inhibiting adipogenic differentiation, promoting lipid hydrolysis, and promoting apoptosis.


  • Open Access

    Microvesicle-Shuttled microRNA-130b Activates the Hepatic Inflammation by Inhibiting Glucocorticoid-Receptor-Mediated Immunosuppression in High-Fat Diet-Induced Obese Mice

    by Zhengqiang Han, Lijun Wang, Shiyong Xu, Horsen Zhang, Ji Cheng, Shifeng Pan

    Metabolism-disorder-induced liver diseases have become increasingly prevalent worldwide and are clinically linked to obesity and type 2 diabetes. In addition, a large number of previous literature studies have indicated that plasma miR-130b is a promising biomarker for the early diagnosis and treatment of obesity. However, whether miRNA-130b that was positively correlated with obesity resulted in hepatic inflammation needs to be further studied. Therefore, the study aims to determine the effect of microvesicle-shuttled miRNA-130b (miR-130b-MV) on the hepatic inflammation and its potential mechanism in high-fat diet-induced obese mice. Three-week-old C57BL/6 mice were fed a high-fat diet for eight weeks. Then, the obese mice received tail vein injections of MV-packaged scrambled control microRNA (miR-SC-MV) or miR-130b-MV every other day for 10 days. Compared with the control group, the miR-130b-MV injection significantly reduced the body weight while increasing the ratio of liver wet weight to total body weight. In addition, the miR-130b-MV injection significantly activated the hepatic inflammation by increasing the expression of proinflammatory genes, although the plasma concentrations of IL-6 and TNF-α were only slightly increased. Furthermore, the miR-130b-MV injection significantly increased the hepatic miR-130b expression while significantly suppressing the protein expression and phosphorylation of GR, a potential target of miR-130b. Moreover, the miR-130b overexpression results in a decrease in the expression of endogenous GR protein and a decrease in the activity of the luciferase reporter of GR 3′-UTR. In addition, the miR-130b-MV injection significantly upregulated NF-kB (p50) in both the cytoplasm and nucleus, showing enhanced proinflammation response. The above results demonstrated that miR-130b-MV activated the hepatic inflammation by inhibiting GR-mediated immunosuppression in high-fat diet-induced obese mice, suggesting a novel mechanism underlying the obesity-induced hepatic inflammation, and the inhibition of miR-130b may serve as a new molecular therapeutic target for the prevention and treatment of hepatic inflammation.